<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36322237</PMID><DateCompleted><Year>2023</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1459</ISSN><JournalIssue CitedMedium="Internet"><Volume>270</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Journal of neurology</Title><ISOAbbreviation>J Neurol</ISOAbbreviation></Journal><ArticleTitle>Brain metabolic differences between pure bulbar and pure spinal ALS: a 2-[<sup>18</sup>F]FDG-PET study.</ArticleTitle><Pagination><StartPage>953</StartPage><EndPage>959</EndPage><MedlinePgn>953-959</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00415-022-11445-9</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">MRI studies reported that ALS patients with bulbar and spinal onset showed focal cortical changes in corresponding regions of the motor homunculus. We evaluated the capability of brain 2-[<sup>18</sup>F]FDG-PET to disclose the metabolic features characterizing patients with pure bulbar or spinal motor impairment.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We classified as pure bulbar (PB) patients with bulbar onset and a normal score in the spinal items of the ALSFRS-R, and as pure spinal (PS) patients with spinal onset and a normal score in the bulbar items at the time of PET. Forty healthy controls (HC) were enrolled. We compared PB and PS, and each patient group with HC. Metabolic clusters showing a statistically significant difference between PB and PS were tested to evaluate their accuracy in discriminating the two groups. We performed a leave-one-out cross-validation (LOOCV) over the entire dataset. Four classifiers were considered: support vector machines (SVM), K-nearest neighbours, linear classifier, and decision tree. Then, we used a separate test set, including 10% of patients, with the remaining 90% composing the training set.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 63&#xa0;PB, 271 PS, and 40 HC. PB showed a relative hypometabolism compared to PS in bilateral precentral gyrus in the regions of the motor cortex involved in the control of bulbar function. SVM showed the best performance, resulting in the lowest error rate in both LOOCV (4.19%) and test set (9.09&#x2009;&#xb1;&#x2009;2.02%).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our data support the concept of the focality of ALS onset and the use of 2-[<sup>18</sup>F]FDG-PET as a biomarker for precision medicine-oriented clinical trials.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Canosa</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5876-4079</Identifier><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; Della Salute E Della Scienza Di Torino, SC Neurologia 1U, Turin, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy. antonio.canosa@unito.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martino</LastName><ForeName>Alessio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Business and Management, LUISS University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giuliani</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Environment and Health Department, Istituto Superiore Di Sanit&#xe0;, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moglia</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; Della Salute E Della Scienza Di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vasta</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grassano</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Palumbo</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cabras</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Pede</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Mattei</LastName><ForeName>Filippo</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matteoni</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polverari</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Positron Emission Tomography Centre AFFIDEA-IRMET S.P.A., Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manera</LastName><ForeName>Umberto</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; Della Salute E Della Scienza Di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calvo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; Della Salute E Della Scienza Di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Pagani</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Radiation Physics and Nuclear Medicine, Karolinska University Hospital, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chi&#xf2;</LastName><ForeName>Adriano</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ALS Centre, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Via Cherasco 15, 10126, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Azienda Ospedaliero-Universitaria Citt&#xe0; Della Salute E Della Scienza Di Torino, SC Neurologia 1U, Turin, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Cognitive Sciences and Technologies, C.N.R., Rome, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Neuroscience Institute of Turin (NIT), Turin, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PRIN 2017 (grant 2017SNW5MB)</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>The Joint Programme - Neurodegenerative Disease Research (Strength</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>ALS-Care</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>Brain Mend projects)</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>Department of Excellence grant</GrantID><Agency>Ministero dell'Istruzione, dell'Universit&#xe0; e della Ricerca</Agency><Country/></Grant><Grant><GrantID>INSPIRED Project</GrantID><Agency>Fondation Thierry Latran</Agency><Country/></Grant><Grant><GrantID>RF-2016-02362405</GrantID><Agency>Ministero della Salute</Agency><Country/></Grant><Grant><GrantID>Health Seventh Framework Programme (FP7/2007-2013</GrantID><Agency>European Commission</Agency><Country/></Grant><Grant><GrantID>grant agreement 259867)</GrantID><Agency>European Commission</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>J Neurol</MedlineTA><NlmUniqueID>0423161</NlmUniqueID><ISSNLinking>0340-5354</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0Z5B2CJX4D</RegistryNumber><NameOfSubstance UI="D019788">Fluorodeoxyglucose F18</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019788" MajorTopicYN="N">Fluorodeoxyglucose F18</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009044" MajorTopicYN="Y">Motor Cortex</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008279" MajorTopicYN="N">Magnetic Resonance Imaging</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Positron emission tomography</Keyword></KeywordList><CoiStatement>Antonio Canosa, Alessio Martino, Alessandro Giuliani, Cristina Moglia, Rosario Vasta, Maurizio Grassano, Francesca Palumbo, Sara Cabras, Francesca Di Pede, Filippo De Mattei, Enrico Matteoni, Giulia Polverari, Umberto Manera, and Marco Pagani report no disclosures relevant to the manuscript. Andrea Calvo has received a research grant from Cytokinetics. Adriano Chi&#xf2; serves on scientific advisory boards for Mitsubishi Tanabe, Roche, Biogen, Cytokinetics, Denali Therapeutics, Amylyx, and AveXis.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>10</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>2</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36322237</ArticleId><ArticleId IdType="pmc">PMC9886651</ArticleId><ArticleId IdType="doi">10.1007/s00415-022-11445-9</ArticleId><ArticleId IdType="pii">10.1007/s00415-022-11445-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Es MA, Hardiman O, Chio A, et al. Amyotrophic lateral sclerosis. Lancet Lond Engl. 2017;390:2084&#x2013;2098. doi: 10.1016/S0140-6736(17)31287-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(17)31287-4</ArticleId><ArticleId IdType="pubmed">28552366</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravits JM, La Spada AR. ALS motor phenotype heterogeneity, focality, and spread: deconstructing motor neuron degeneration. Neurology. 2009;73:805&#x2013;811. doi: 10.1212/WNL.0b013e3181b6bbbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181b6bbbd</ArticleId><ArticleId IdType="pmc">PMC2739608</ArticleId><ArticleId IdType="pubmed">19738176</ArticleId></ArticleIdList></Reference><Reference><Citation>Bede P, Bokde A, Elamin M, et al. Grey matter correlates of clinical variables in amyotrophic lateral sclerosis (ALS): a neuroimaging study of ALS motor phenotype heterogeneity and cortical focality. J Neurol Neurosurg Psychiatry. 2013;84:766&#x2013;773. doi: 10.1136/jnnp-2012-302674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-302674</ArticleId><ArticleId IdType="pubmed">23085933</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster C, Kasper E, Machts J, et al. Focal thinning of the motor cortex mirrors clinical features of amyotrophic lateral sclerosis and their phenotypes: a neuroimaging study. J Neurol. 2013;260:2856&#x2013;2864. doi: 10.1007/s00415-013-7083-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-013-7083-z</ArticleId><ArticleId IdType="pubmed">23996101</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin J, Hu F, Zhang Q, et al. Dominant heterogeneity of upper and lower motor neuron degeneration to motor manifestation of involved region in amyotrophic lateral sclerosis. Sci Rep. 2019;9:20059. doi: 10.1038/s41598-019-56665-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56665-8</ArticleId><ArticleId IdType="pmc">PMC6934517</ArticleId><ArticleId IdType="pubmed">31882886</ArticleId></ArticleIdList></Reference><Reference><Citation>Pagani M, Chi&#xf2; A, Valentini MC, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067&#x2013;1074. doi: 10.1212/WNL.0000000000000792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000000792</ArticleId><ArticleId IdType="pubmed">25122207</ArticleId></ArticleIdList></Reference><Reference><Citation>Cistaro A, Valentini MC, Chi&#xf2; A, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251&#x2013;259. doi: 10.1007/s00259-011-1979-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-011-1979-6</ArticleId><ArticleId IdType="pubmed">22089661</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Laere K, Vanhee A, Verschueren J, et al. Value of 18fluorodeoxyglucose-positron-emission tomography in amyotrophic lateral sclerosis: a prospective study. JAMA Neurol. 2014;71:553&#x2013;561. doi: 10.1001/jamaneurol.2014.62.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamaneurol.2014.62</ArticleId><ArticleId IdType="pubmed">24615479</ArticleId></ArticleIdList></Reference><Reference><Citation>Sala A, Iaccarino L, Fania P, et al. Testing the diagnostic accuracy of [18F]FDG-PET in discriminating spinal- and bulbar-onset amyotrophic lateral sclerosis. Eur J Nucl Med Mol Imaging. 2019;46:1117&#x2013;1131. doi: 10.1007/s00259-018-4246-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-018-4246-2</ArticleId><ArticleId IdType="pubmed">30617963</ArticleId></ArticleIdList></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, et al. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Mot Neuron Disord. 2000;1:293&#x2013;299. doi: 10.1080/146608200300079536.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Balendra R, Jones A, Jivraj N, et al. Estimating clinical stage of amyotrophic lateral sclerosis from the ALS functional rating scale. Amyotroph Lateral Scler Front Degener. 2014;15:279&#x2013;284. doi: 10.3109/21678421.2014.897357.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.897357</ArticleId><ArticleId IdType="pubmed">24720420</ArticleId></ArticleIdList></Reference><Reference><Citation>Varrone A, Asenbaum S, Vander Borght T, et al. EANM procedure guidelines for PET brain imaging using [18F]FDG, version 2. Eur J Nucl Med Mol Imaging. 2009;36:2103&#x2013;2110. doi: 10.1007/s00259-009-1264-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-009-1264-0</ArticleId><ArticleId IdType="pubmed">19838705</ArticleId></ArticleIdList></Reference><Reference><Citation>Della Rosa PA, Cerami C, Gallivanone F, et al. A standardized [18F]-FDG-PET template for spatial normalization in statistical parametric mapping of dementia. Neuroinformatics. 2014;12:575&#x2013;593. doi: 10.1007/s12021-014-9235-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-014-9235-4</ArticleId><ArticleId IdType="pubmed">24952892</ArticleId></ArticleIdList></Reference><Reference><Citation>Canosa A, Calvo A, Moglia C, et al. Brain metabolic changes across King&#x2019;s stages in amyotrophic lateral sclerosis: a 18F&#x2013;2-fluoro-2-deoxy-D-glucose-positron emission tomography study. Eur J Nucl Med Mol Imaging. 2021;48:1124&#x2013;1133. doi: 10.1007/s00259-020-05053-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00259-020-05053-w</ArticleId><ArticleId IdType="pmc">PMC8041703</ArticleId><ArticleId IdType="pubmed">33029654</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M, Figueiral M, Uysal H, et al. Spreading in ALS: The relative impact of upper and lower motor neuron involvement. Ann Clin Transl Neurol. 2020;7:1181&#x2013;1192. doi: 10.1002/acn3.51098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.51098</ArticleId><ArticleId IdType="pmc">PMC7359118</ArticleId><ArticleId IdType="pubmed">32558369</ArticleId></ArticleIdList></Reference><Reference><Citation>Dharmadasa T, Matamala JM, Howells J, et al. Early focality and spread of cortical dysfunction in amyotrophic lateral sclerosis: A regional study across the motor cortices. Clin Neurophysiol. 2020;131:958&#x2013;966. doi: 10.1016/j.clinph.2019.11.057.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinph.2019.11.057</ArticleId><ArticleId IdType="pubmed">31959568</ArticleId></ArticleIdList></Reference><Reference><Citation>Steinbach R, Prell T, Gaur N, et al. Patterns of grey and white matter changes differ between bulbar and limb onset amyotrophic lateral sclerosis. NeuroImage Clin. 2021;30:102674. doi: 10.1016/j.nicl.2021.102674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nicl.2021.102674</ArticleId><ArticleId IdType="pmc">PMC8099783</ArticleId><ArticleId IdType="pubmed">33901988</ArticleId></ArticleIdList></Reference><Reference><Citation>Campanari M-L, Bourefis A-R, Kabashi E. Diagnostic challenge and neuromuscular junction contribution to ALS pathogenesis. Front Neurol. 2019;10:68. doi: 10.3389/fneur.2019.00068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00068</ArticleId><ArticleId IdType="pmc">PMC6372519</ArticleId><ArticleId IdType="pubmed">30787905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ib&#xe1;&#xf1;ez V, Pietrini P, Alexander GE, et al. Regional glucose metabolic abnormalities are not the result of atrophy in Alzheimer&#x2019;s disease. Neurology. 1998;50:1585&#x2013;1593. doi: 10.1212/wnl.50.6.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/wnl.50.6.1585</ArticleId><ArticleId IdType="pubmed">9633698</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>